WO2004087181A2 - WIRKSTOFFKOMBINATION VON ω3-FETTSÄUREHALTIGEN ÖLEN MIT POLYPHENOLHALTIGEN PFLANZENEXTRAKTEN UND DEREN VERWENDUNG - Google Patents
WIRKSTOFFKOMBINATION VON ω3-FETTSÄUREHALTIGEN ÖLEN MIT POLYPHENOLHALTIGEN PFLANZENEXTRAKTEN UND DEREN VERWENDUNG Download PDFInfo
- Publication number
- WO2004087181A2 WO2004087181A2 PCT/EP2004/003401 EP2004003401W WO2004087181A2 WO 2004087181 A2 WO2004087181 A2 WO 2004087181A2 EP 2004003401 W EP2004003401 W EP 2004003401W WO 2004087181 A2 WO2004087181 A2 WO 2004087181A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- diseases
- active ingredient
- oil
- treatment
- ingredient combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/55—Linaceae (Flax family), e.g. Linum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Definitions
- the present invention relates to active ingredient combinations of ⁇ 3-fatty acid-containing oils with polyphenolic-containing plant extracts and their use for the treatment of inflammatory and / or immunological and metabolic diseases and other disorders.
- ⁇ 3 fatty acids are responsible for the • disease process in chronic inflammatory and / or immunological diseases, such as ⁇ .
- B. favorably affect atherosclerosis, coronary heart disease, rheumatoid arthritis, psoriasis etc. It is also reported that these fatty acids have preventive and protective effects in fat metabolism disorders or diabetes and are therefore suitable for the treatment of vascular and neurological disorders, such as those that occur in these diseases.
- ⁇ 3 fatty acids With a lack of ⁇ 3 fatty acids in the diet, visual and central nervous disorders as well as hemorrhagic dermatitis, growth disorders and delayed wound healing were observed. Since the mammal organism is unable to synthesize these compounds itself, it is dependent on food.
- ⁇ 3 fatty acids prevent the formation of pro-inflammatory prostaglandins and leukotrienes from arachidonic acid by displacing this fatty acid from its binding in the SN2 position of phospholipids in the cell membranes.
- Polyunsaturated fatty acids such as B. ⁇ -linolenic acid, eicosapentaenoic acid or docosahexaenoic acid are extremely sensitive to oxidation. The incorporation such fatty acids or their secondary products in cellular membranes therefore increases the organism's need for antioxidants.
- polyphenols includes simple phenol carboxylic acids such as. As gentisic acid, protocatechic acid, gallic acid or caffeic acid, flavones such as. As camphor oil, quercetin, myricetin, isorhamnetin, naringenin, 6-prenylnaringenin, 8-prenylnaringenin, isoxanthohumol and their glycosides, chalcones such as. B. xanthohumol, isoflavones such as. B.
- anthocyanins such as. As pelargonidine, cyanidine, malvidin or delphinidine, tanning agents such as. B. catechin and epicatechin, their oligomers and polymers and lignans. All of these compounds are reducing agents and, along with other antioxidant substances, e.g. As vitamins C and E, to protect the body against oxidative stress. Oxidative stress is a condition in the body in which the formation of oxidants and free radicals exceeds the body's ability to inactivate these substances. As a result, proteins, DNA and lipids as well as cell membranes and other structural elements are damaged.
- oxidation products are involved in the development of common diseases such as atherosclerosis, chronic inflammation, cancer or diabetes and accelerate the aging process.
- the amount of free radicals depends on lifestyle (diet, smoking, exercise) and is influenced by existing illnesses (eg hypercholesterolemia, diabetes).
- a particularly rich source of oxygen radicals are e.g. B. neutrophilic granulocytes, which release these compounds in inflammatory reactions. Since endogenously formed molecules or enzymes with an antioxidative effect cannot be influenced in their concentration or activity by exogenous measures, the intake of antioxidants via nutrition is of crucial importance.
- the object of the present invention is to provide means for the prevention and treatment of inflammatory and immunological diseases and of tumor disorders.
- This object is achieved by a combination of active ingredients comprising at least one oil containing ⁇ 3 fatty acid and at least one plant extract containing polyphenol, which at the same time compensates for a deficiency in ⁇ 3 fatty acids and antioxidative polyphenols, prevents such a deficiency or an increased need for these substances in the case of inflammatory and / or immunological and metabolic diseases and tumor disorders.
- this combination of active substances counteracts two important factors involved in the pathogenesis of inflammatory reactions and metabolic diseases. It also has the advantage that the oxidation-sensitive ⁇ 3 fatty acids are protected from degradation by the antioxidative action of the polyphenols and / or vitamins both during storage and after incorporation in cell membranes.
- a preferred ⁇ 3 fatty acid is ⁇ -linolenic acid, which is contained, for example, about 50-60% in the oil from the seeds of Perilla frutescens (Perillaöll). For this reason, perilla oil is a preferred ⁇ 3 fatty acid oil.
- suitable oils include borage oil, evening primrose seed oil, fish oil, currant seed oil and linseed oil.
- Preferred polyphenol-containing plant extracts are extracts from Aspalathus linearis, Crataegus species, Ginkgo biloba, Humulus lupulus, Hypericum perforatum, Paullinia cupana, Rubus fructicosus, Rubus idaeus, Tabebuia avellanedae, The obroma cacao, Vaccinium myrtilla and Vitis vinifer.
- the polyphenol-containing plant extract preferably contains at least 15% by weight of polyphenols, based on the dry extract.
- Active substance combinations which contain one of the following combinations are preferred: extract from Vitis vinifera and perilla seed oil, extract from Vaccinium myrtillus and linseed oil, extract from ginkgo biloba and linseed oil, extract from crataegus and borage oil, extract from Aspalathus linearis and borage oil, extract from Theobroma cacao and evening primrose seed oil, extract from Tabebuia avellanedae and evening primrose seed oil, extract from fish oil, extract from Hypericumupulus and undatum Fish oil, extract from Paullinia cupana and currant kernel oil, extract from Rubus idaeus and currant kernel oil, extract from Rubus fructicosus and perilla seed oil, extract from Aspalathus linearis and perilla seed oil as well as extract from Humulus lupulus and perilla seed oil.
- the extracts can be prepared in a variable composition with solvents such as e.g. B. water, methanol, ethanol, 2-propanol, acetone, etc. and mixtures thereof at temperatures from room temperatures to 100 ° C with gentle to vigorous mixing or by percolation within 10 minutes to 24 hours under normal pressure or elevated pressure be preserved.
- solvents such as e.g. B. water, methanol, ethanol, 2-propanol, acetone, etc. and mixtures thereof at temperatures from room temperatures to 100 ° C with gentle to vigorous mixing or by percolation within 10 minutes to 24 hours under normal pressure or elevated pressure be preserved.
- further concentration steps can be carried out, e.g. B. liquid-liquid distribution with z. B. 1-butanol water or ethyl acetate / water, adsorption-desorption on ion exchanger, LH20, HP20 and other resins or chromatographic separations over RP18, silica gel, etc.
- the further processing to dry extracts is
- the active substance combinations according to the invention can be used for the treatment, for the support of the treatment or for the prophylaxis of inflammatory and / or immunological and metabolic diseases and other disorders, such as, for. B. rheumatoid arthritis, polyarthritis, synovitis, acne, neurodermatitis, psoriasis, asthma, hay fever, atherosclerosis, coronary heart disease or arrhythmia, of chronic bowel diseases, such as. B. ulcerative colitis or Crohn's disease, as well as polyneuropathies, retinopathies, cerebral and peripheral arterial circulatory disorders, psychiatric disorders such as. B. depression, schizophrenia, bipolar disorder, and tumor diseases.
- rheumatoid arthritis polyarthritis, synovitis, acne, neurodermatitis, psoriasis, asthma, hay fever, atherosclerosis, coronary heart disease or arrhythmia
- chronic bowel diseases such as. B. ulcerative colitis or Crohn's disease,
- the active ingredient combination according to the invention can be in the form of a dietetic food or pharmaceutical.
- the active substance combinations according to the invention are preferably administered as part of a balanced diet.
- the drug combinations can additional components such.
- B. Vitamin C and / or E are added to compensate for their deficiency or to ensure their increased need.
- the active substance combinations according to the invention are well suited for filling into capsules.
- other substances such as B. partially or fully hydrogenated vegetable oils, beeswax, lecithin, neutral oil, hard fat and highly disperse silicon dioxide can be added to the capsule filling compound in order to adjust the consistency of the mixtures and to prevent segregation of the liquid component and solid plant extract.
- amphiphilic, surface-active substances and emulsifiers such as. B. Sorbitan monooleate can be added.
- the plant extract is mixed with the oil (both according to the table below) and the flowable suspension obtained is filled into capsules using a suitable method.
- ⁇ 3-fatty acid-containing oils and polyphenol-containing plant extracts described in the preceding examples are distinguished by the fact that they inhibit the synthesis of pro-inflammatory eicosanoids and the neutralization of free radicals. They also have the advantage that the oxidation-sensitive ⁇ 3 fatty acids are protected from degradation by the antioxidative effect of the polyphenols both during storage and after incorporation in cell membranes.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA05010416A MXPA05010416A (es) | 2003-04-02 | 2004-03-31 | Combinacion de substancias activas de aceites minerales que contienen acidos grasos (3 con extractos vegetales que contengan polifenoles y su uso. |
EP04724578A EP1608387A2 (de) | 2003-04-02 | 2004-03-31 | WIRKSTOFFKOMBINATION VON w3-FETTSÄUREHALTIGEN ÖLEN MIT POLYPHENOLHALTIGEN PFLANZENEXTRAKTEN UND DEREN VERWENDUNG |
CA002521040A CA2521040A1 (en) | 2003-04-02 | 2004-03-31 | Active ingredient combinations of plant oils containing .omega.3-fatty acids and plant extracts containing polyphenols and the use thereof |
BRPI0409139-6A BRPI0409139A (pt) | 2003-04-02 | 2004-03-31 | combinação de ingredientes ativos de óleos que contêm ácido graxo w3 com extratos de plantas que contêm polifenol e uso destes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10315025A DE10315025A1 (de) | 2003-04-02 | 2003-04-02 | Wirkstoffkombination von ω3-fettsäurehaltigen Ölen mit polyphenolhaltigen Pflanzenextrakten und deren Verwendung |
DE10315025.0 | 2003-04-02 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2004087181A2 true WO2004087181A2 (de) | 2004-10-14 |
WO2004087181A8 WO2004087181A8 (de) | 2004-12-29 |
WO2004087181A3 WO2004087181A3 (de) | 2005-04-21 |
Family
ID=32980960
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/003401 WO2004087181A2 (de) | 2003-04-02 | 2004-03-31 | WIRKSTOFFKOMBINATION VON ω3-FETTSÄUREHALTIGEN ÖLEN MIT POLYPHENOLHALTIGEN PFLANZENEXTRAKTEN UND DEREN VERWENDUNG |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1608387A2 (de) |
BR (1) | BRPI0409139A (de) |
CA (1) | CA2521040A1 (de) |
DE (1) | DE10315025A1 (de) |
MX (1) | MXPA05010416A (de) |
RU (1) | RU2005130342A (de) |
WO (1) | WO2004087181A2 (de) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1618875A1 (de) * | 2003-04-08 | 2006-01-25 | Kirin Beer Kabushiki Kaisha | Zusammensetzung zur hemmung oder prävention der verringerung der knochendichte und regenerierung dafür |
WO2006120360A2 (fr) * | 2005-05-13 | 2006-11-16 | Persee Medica | Composition pour traiter ou prevenir les troubles liés à un dérèglement de l'horloge biologique |
EP2135616A1 (de) * | 2008-06-19 | 2009-12-23 | Symrise GmbH & Co. KG | Getrocknete Vacciniumfrüchte zur Beeinflussung von Zuständen des Darmes |
WO2010000564A2 (en) * | 2008-06-09 | 2010-01-07 | Nestec S.A. | Rooibos and inflammation |
US8597692B2 (en) | 2007-04-26 | 2013-12-03 | Barry Callebaut Ag | Cocoa extract and use thereof |
US8603547B2 (en) | 2007-04-26 | 2013-12-10 | Barry Callebaut Ag | Use of cocoa extract |
US8709503B2 (en) | 2007-04-26 | 2014-04-29 | Barry Callebaut Ag | Use of cocoa extract |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8257751B2 (en) * | 2003-11-03 | 2012-09-04 | Beauté Pacifique ApS | Composition for the cosmetic treatment of age-related dermatological symptoms |
DE102005035864A1 (de) * | 2005-07-30 | 2007-02-01 | Beiersdorf Ag | Verwendung von Xanthohumol und/oder Isoxanthohumol zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Behandlung und/oder Prophylaxe der Symptome der intrinsischen und/oder extrinsischen Hautalterung sowie zur Behandlung und Prophylaxe der schädlichen Auswirkungen ultravioletter Strahlung auf die Haut |
DE102006033321A1 (de) * | 2006-07-17 | 2008-01-24 | Westfälische Wilhelms-Universität Münster | Medizinische Verwendung von N-Phenylpropenoyl-Aminosäurederivaten und verwandten Verbindungen |
FR2912918A1 (fr) * | 2007-02-27 | 2008-08-29 | Persee Medica Soc Par Actions | Utilisation d'acides gras polyinsatures et de flavonoides en tant qu'agents actifs dans une composition pour la prevention et/ou le traitement des cephalees. |
WO2015154192A1 (en) * | 2014-04-11 | 2015-10-15 | George Robertson | Use of a composition comprising a flavonol, a flavonoid, and a fatty acid in the treatment of oxidative injuries due to mitochondrial dysfunction |
CN109316535A (zh) * | 2017-07-31 | 2019-02-12 | 格特生物制药(天津)有限公司 | 一种治疗鸡滑膜炎的中药组合物及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2770974A1 (fr) * | 1997-11-20 | 1999-05-21 | Hatem Smaoui | Nouveau complement nutritionnel a base de lycopene de tomate, d'acides gras r 3-6-9 et antioxydants primaires et secondaires |
WO2004087114A1 (de) * | 2003-04-02 | 2004-10-14 | Bioplanta Arzneimittel Gmbh | Kapseln mit verzögerter freisetzung durch in der kapsel enthaltenden polyphenolhaltigen pflanzenextrakt |
WO2004087180A1 (de) * | 2003-04-02 | 2004-10-14 | Bioplanta Arzneimittel Gmbh | Zusammensetzungen enthaltend omega-3-fettsäurehaltige öle und pflanzenextrakte |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0558901A (ja) * | 1991-08-26 | 1993-03-09 | Teikoku Hormone Mfg Co Ltd | 骨吸収抑制因子およびその製造方法 |
-
2003
- 2003-04-02 DE DE10315025A patent/DE10315025A1/de not_active Withdrawn
-
2004
- 2004-03-31 WO PCT/EP2004/003401 patent/WO2004087181A2/de active Search and Examination
- 2004-03-31 BR BRPI0409139-6A patent/BRPI0409139A/pt not_active IP Right Cessation
- 2004-03-31 MX MXPA05010416A patent/MXPA05010416A/es not_active Application Discontinuation
- 2004-03-31 EP EP04724578A patent/EP1608387A2/de not_active Withdrawn
- 2004-03-31 RU RU2005130342/15A patent/RU2005130342A/ru not_active Application Discontinuation
- 2004-03-31 CA CA002521040A patent/CA2521040A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2770974A1 (fr) * | 1997-11-20 | 1999-05-21 | Hatem Smaoui | Nouveau complement nutritionnel a base de lycopene de tomate, d'acides gras r 3-6-9 et antioxydants primaires et secondaires |
WO2004087114A1 (de) * | 2003-04-02 | 2004-10-14 | Bioplanta Arzneimittel Gmbh | Kapseln mit verzögerter freisetzung durch in der kapsel enthaltenden polyphenolhaltigen pflanzenextrakt |
WO2004087180A1 (de) * | 2003-04-02 | 2004-10-14 | Bioplanta Arzneimittel Gmbh | Zusammensetzungen enthaltend omega-3-fettsäurehaltige öle und pflanzenextrakte |
Non-Patent Citations (12)
Title |
---|
CZYGAN F-C: "Redbush-tea - Aspalathus linearis" ZEITSCHRIFT FUR PHYTOTHERAPIE 2002 GERMANY, Bd. 23, Nr. 6, 2002, Seiten 295-298, XP009033111 ISSN: 0722-348X * |
DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; Dezember 1999 (1999-12), KANG HAN-CHUL ET AL: "Extraction and mixing effects of grape (Campbell) seed oil" XP002308812 Database accession no. PREV200000129154 & AGRICULTURAL CHEMISTRY AND BIOTECHNOLOGY, Bd. 42, Nr. 4, Dezember 1999 (1999-12), Seiten 175-179, ISSN: 0368-2897 * |
DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; Juni 1998 (1998-06), LEE BONG-HO ET AL: "References review of the scientific researches on perilla" XP002308811 Database accession no. PREV199800504419 & RDA JOURNAL OF INDUSTRIAL CROP SCIENCE, Bd. 40, Nr. 1, Juni 1998 (1998-06), Seiten 80-112, ISSN: 1226-5624 * |
FREMONT LUCIE ET AL: "Antioxidant activity of resveratrol and alcohol-free wine polyphenols related to LDL oxidation and polyunsaturated fatty acids" LIFE SCIENCES, Bd. 64, Nr. 26, 21. Mai 1999 (1999-05-21), Seiten 2511-2521, XP002308810 ISSN: 0024-3205 * |
GRIMM H ET AL: "Regulatory potential of n-3 fatty acids in immunological and inflammatory processes" BRITISH JOURNAL OF NUTRITION, Bd. 87, Nr. Supplement 1, Januar 2002 (2002-01), Seiten S59-S67, XP009033127 ISSN: 0007-1145 * |
GRIMMINGER F ET AL: "Use of n-3 fatty acid-containing lipid emulsions in the intensive care unit environment: The clinician's view" CLINICAL NUTRITION 2002 UNITED KINGDOM, Bd. 21, Nr. SUPPL. 2, 2002, Seiten 23-29, XP009033130 ISSN: 0261-5614 * |
JOUBERT E ET AL: "Antioxidants of rooibos tea - a possible explanation for its health promoting properties?" SOUTH AFRICAN JOURNAL OF FOOD SCIENCE AND NUTRITION 1996 INFRUITEC, PRIVATE BAG X5013, STELLENBOSCH 7599, SOUTH AFRICA, Bd. 8, Nr. 3, 1996, Seite 79, XP009033126 * |
NARISAWA T ET AL: "COLON CANCER PRECENTION WITH A SMALL AMOUNT OF DIETARY PERILLA IOL HIGH IN ALPHA-LNOLENIC ACID IN AN ANIMAL MODEL" CANCER, AMERICAN CANCER SOCIETY, PHILADELPHIA, PA, US, Bd. 73, Nr. 8, 15. April 1994 (1994-04-15), Seiten 2069-2075, XP001037789 ISSN: 0008-543X * |
PATENT ABSTRACTS OF JAPAN Bd. 0173, Nr. 67 (C-1082), 12. Juli 1993 (1993-07-12) & JP 05 058901 A (TEIKOKU HORMONE MFG CO LTD), 9. März 1993 (1993-03-09) * |
SCHULZ H: "Red bush in cosmetics" COSSMA 2000 GERMANY, Bd. 1, Nr. 4, 2000, Seiten 22-23, XP009033110 ISSN: 1439-7676 * |
See also references of EP1608387A2 * |
YOSHINO KYOJI ET AL: "Antioxidative and hypolipidemic effects of dietary green tea polyphenols in ddY mice fed fish oil-rich diet" JOURNAL OF THE FOOD HYGIENIC SOCIETY OF JAPAN, Bd. 39, Nr. 3, Juni 1998 (1998-06), Seiten 192-198, XP009033072 ISSN: 0015-6426 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1618875A1 (de) * | 2003-04-08 | 2006-01-25 | Kirin Beer Kabushiki Kaisha | Zusammensetzung zur hemmung oder prävention der verringerung der knochendichte und regenerierung dafür |
EP1618875A4 (de) * | 2003-04-08 | 2006-05-24 | Kirin Brewery | Zusammensetzung zur hemmung oder prävention der verringerung der knochendichte und regenerierung dafür |
WO2006120360A2 (fr) * | 2005-05-13 | 2006-11-16 | Persee Medica | Composition pour traiter ou prevenir les troubles liés à un dérèglement de l'horloge biologique |
WO2006120360A3 (fr) * | 2005-05-13 | 2007-11-08 | Persee Medica | Composition pour traiter ou prevenir les troubles liés à un dérèglement de l'horloge biologique |
US8597692B2 (en) | 2007-04-26 | 2013-12-03 | Barry Callebaut Ag | Cocoa extract and use thereof |
US8603547B2 (en) | 2007-04-26 | 2013-12-10 | Barry Callebaut Ag | Use of cocoa extract |
US8709503B2 (en) | 2007-04-26 | 2014-04-29 | Barry Callebaut Ag | Use of cocoa extract |
WO2010000564A2 (en) * | 2008-06-09 | 2010-01-07 | Nestec S.A. | Rooibos and inflammation |
EP2133088A3 (de) * | 2008-06-09 | 2010-01-27 | Nestec S.A. | Rooibos und Entzündung |
WO2010000564A3 (en) * | 2008-06-09 | 2010-02-25 | Nestec S.A. | Rooibos and inflammation |
EP2135616A1 (de) * | 2008-06-19 | 2009-12-23 | Symrise GmbH & Co. KG | Getrocknete Vacciniumfrüchte zur Beeinflussung von Zuständen des Darmes |
EP2135616B1 (de) | 2008-06-19 | 2016-05-04 | Symrise AG | Getrocknete Vacciniumfrüchte zur Beeinflussung von Zuständen des Darmes |
Also Published As
Publication number | Publication date |
---|---|
WO2004087181A8 (de) | 2004-12-29 |
CA2521040A1 (en) | 2004-10-14 |
BRPI0409139A (pt) | 2006-03-28 |
WO2004087181A3 (de) | 2005-04-21 |
DE10315025A1 (de) | 2004-10-14 |
EP1608387A2 (de) | 2005-12-28 |
RU2005130342A (ru) | 2006-03-27 |
MXPA05010416A (es) | 2006-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60122196T2 (de) | Synergistische antioxidans-kombination von delta tocols und polyphenolen | |
AT407821B (de) | Mittel auf der basis von naturstoffen | |
DE60012709T2 (de) | Nahrungsergänzungsmittel und verfahren zur kosmetischen behandlung unter verwendung von einem polyphenolreichen traubenextrakt | |
KR20170102932A (ko) | 복합 보충제 조성물 | |
EP1377273B1 (de) | Verfahren zur herstellung eines isoflavon-konzentrats | |
WO2004087181A2 (de) | WIRKSTOFFKOMBINATION VON ω3-FETTSÄUREHALTIGEN ÖLEN MIT POLYPHENOLHALTIGEN PFLANZENEXTRAKTEN UND DEREN VERWENDUNG | |
EP3651805A2 (de) | Solubilisat mit curcumin und optional zumindest einem weiteren wirkstoff | |
US9034399B2 (en) | Dietary compositions for promoting brain health | |
EP1091659B1 (de) | Orale darreichungsform | |
EP1305013A1 (de) | Präparat mit gefässschützender und antioxidativer wirkung sowie dessen verwendung | |
EP2282751B1 (de) | Kompartimentspezifische pflanzenextraktkombination aus ginkgo biloba- und ginseng-extrakt mit tandemwirkung | |
DE10315026A1 (de) | Zusammensetzungen enthaltend omega-3-fettsäurehaltige Öle und Pflanzenextrakte | |
WO2004087114A1 (de) | Kapseln mit verzögerter freisetzung durch in der kapsel enthaltenden polyphenolhaltigen pflanzenextrakt | |
WO2011042469A1 (de) | Verwendung einer zusammensetzung auf basis von eremophilanoliden | |
JP2000072685A (ja) | 消化器潰瘍を抑制するための食品および医薬組成物 | |
JP2009196967A (ja) | 血中多価不飽和脂肪酸相対量増加剤並びにこれを含有する医薬組成物、医薬部外品、化粧品、可食性組成物及び動物用飼料 | |
EP1541037A1 (de) | Zubereitung zur oralen Aufnahme enthaltend Extrakte von Passiflora incarnata | |
DE102011052708A1 (de) | Verfahren zum Schutz photolabiler Wirkstoffe | |
LU500687B1 (de) | Nahrungs- oder diätische zusammensetzung | |
WO2022162597A1 (en) | Combinations of scutellaria extracts with citrus bergamia or cynara cardunculus extracts and formulations containing them | |
WO2009071564A1 (de) | Pharmazeutische zusammensetzung zur behandlung von malaria | |
DE202023103890U1 (de) | Extrakt aus Amlafrüchten und selbigen beinhaltende Nährstoffzusammensetzung | |
EP4255490A1 (de) | Eutektische matrix für nutrazeutische zusammensetzungen | |
KR20030073995A (ko) | 항염, 항자극 효과가 있는 복령 추출물을 함유하는 화장료조성물과 그의 제조방법 | |
IT202000029747A1 (it) | Composizione ad attivita’ protettiva su cellule neuronali per prevenire e trattare un disturbo neurocognitivo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: IN PCT GAZETTE 42/2004 UNDER (81) REPLACE "DE" BY "DE (UTILITY MODEL)" |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004724578 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/010416 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2521040 Country of ref document: CA Ref document number: 2005130342 Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004724578 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0409139 Country of ref document: BR |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) |